Get to know our clinical trials

Study on the efficacy of the anti-LAG-3 monoclonal antibody (BMS-986016) in monotherapy and in combination with anti-PD-1 (Nivolumab) in advanced solid tumors.

THE MAIN OBJECTIVE OF THIS STUDY IS TO DETERMINE THE SAFETY AND TOLERABILITY OF THE ANTI-LAG-3 ANTIBODY (BMS-986016), ADMINISTERED AS A SINGLE AGENT OR IN COMBINATION WITH THE ANTI-PD-1 ANTIBODY (BMS-936558, NIVOLUMAB) IN SUBJECTS WITH ADVANCED SOLID TUMORS. THIS IS A SUMMARY OF THE CLINICAL TRIAL, ONCE YOU CONTACT US, WE WILL PROVIDE YOU WITH ALL THE INFORMATION YOU NEED.

Status
In recruitment
headquarters
Multisede

Technical Summary

  • PHASE I, DOSE-ESCALATION AND COHORT EXPANSION STUDY, SAFETY, TOLERABILITY, AND EFFICACY OF ANTI-LAG-3 MONOCLONAL ANTIBODY (BMS-986016) ADMINISTERED IN MONOTHERAPY AND IN COMBINATION WITH ANTI-PD-1 MONOCLONAL ANTIBODY (NIVOLUMAB, BMS-936558) IN ADVANCED SOLID TUMORS. IMMUNOTHERAPY
  • Code EudraCT: 2014-002605-38
  • Protocol number: CA224-020
  • Molecule/Drug: BMS-986016 (anticuerpo monoclonal anti-LAG-3)
  • Link to Clinical Trials

* The trials only admit a limited number of patients and are subject to inclusion and exclusion criteria. The specialist who assesses your case will inform you of the conditions required to participate in the clinical trial.

Who can participate?

Patients of both sexes, aged 18 years or older. Histological or cytological confirmation of an incurable solid malignant tumor that is advanced (metastatic and/or unresectable).

Do you want to participate in this trial?

Request an appointment for our specialists to assess whether you qualify for this clinical trial


Do you prefer to send us your reports?

If you prefer, you can send us your medical information and our specialists will evaluate your case without the need to come to the Clinica.